На этой странице перечислены больницы направления «Гинекология» (включая Hormone Replacement Therapy (HRT)) в Бангалор, Индия, включая Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru и другие.
Спросите нас о «Hormone Replacement Therapy (HRT)» в Бангалор, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 10 аккредитованных больниц (Гинекология) в Бангалор, Индия
Рекомендуем🇮🇳 Narayana Health
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 1750 отзывов).
🇮🇳 Manipal Hospitals
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 1450 отзывов).
🇮🇳 Medicover Hospital, Bangalore
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 68 отзывов).
🇮🇳 Gleneagles Hospitals, Bengaluru
Больница занимает 4-е место в этом списке по указанному рейтингу (4.7/5, 142 отзывов).
🇮🇳 Manipal Hospital Malleshwaram (Northside)
Больница занимает 5-е место в этом списке по указанному рейтингу (4.6/5, 71 отзывов).
🇮🇳 Manipal Hospital, Old Airport Road
Больница занимает 6-е место в этом списке по указанному рейтингу (4.5/5, 87 отзывов).
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
Больница занимает 7-е место в этом списке по указанному рейтингу (4.5/5, 98 отзывов).
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.4/5, 74 отзывов).
🇮🇳 Apollo Hospital, Bannerghatta Road
Больница занимает 9-е место в этом списке по указанному рейтингу (4.2/5, 25 отзывов).
🇮🇳 Fortis Hospital, Bannerghatta Road
Больница занимает 10-е место в этом списке по указанному рейтингу (4.2/5, 58 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Гинекология» указано среди её специализаций и она находится в Бангалор, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «hormone replacement therapy (hrt)» в Бангалор, Индия?
Выбор подходящей больницы для «hormone replacement therapy (hrt)» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Гинекология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Hormone Replacement Therapy (HRT)»
Hormone Replacement Therapy (HRT) is a clinically proven medical intervention that restores declining estrogen, progesterone, and testosterone levels in peri- and post-menopausal women, significantly reducing vasomotor symptoms, bone loss, and cardiovascular risk when initiated appropriately. With success rates exceeding 85–90% in symptom relief and quality-of-life improvement, HRT is now delivered through sophisticated, individualized protocols including bioidentical hormone formulations, transdermal patches, subcutaneous pellets, and low-dose vaginal systems. GAF Healthcare connects international patients with leading gynaecological endocrinologists at JCI- and NABH-accredited institutions across India and JCI- and DHA-licensed centres in the UAE, offering expert-guided, cost-transparent care from initial hormone profiling through long-term follow-up. Hospital Stay: 0–1 days (outpatient consultation and initiation; short admission only if procedural pellet insertion is performed) • Total Stay in Country (Fit-to-Fly): 1–3 days after initiation for most systemic HRT forms; 5–7 days if subcutaneous pellet insertion was performed under local anaesthesia • Success Rate: 85–92% significant symptom improvement; ~75% patient continuation at 12 months with optimised regimen
Clinical Overview
Menopause, the permanent cessation of ovarian follicular activity confirmed after 12 consecutive months of amenorrhoea, produces a steep decline in 17β-estradiol from premenopausal levels of 50–400 pg/mL to post-menopausal values below 20 pg/mL. This hypoestrogenic state drives a cascade of physiological consequences: accelerated trabecular bone resorption (increasing vertebral fracture risk by up to 50% within five years), dyslipidaemia with rising LDL and falling HDL, urogenital atrophy causing dyspareunia and recurrent urinary tract infections, and hypothalamic thermoregulatory dysfunction producing vasomotor symptoms—hot flushes and night sweats—in up to 75% of women. Central nervous system effects, including sleep disruption, mood lability, and cognitive fog, further erode quality of life. Surgical menopause secondary to bilateral oophorectomy produces an abrupt, more severe hypoestrogenic state that carries an even greater long-term cardiovascular and skeletal disease burden. Hormone Replacement Therapy addresses these deficits by restoring circulating sex steroid levels to the lower end of the physiological premenopausal range. Current evidence, including re-analysis of the Women's Health Initiative data and data from the KEEPS and ELITE trials, establishes a 'timing hypothesis': women who initiate HRT within ten years of menopause onset or before age 60 derive the greatest cardiovascular and neuroprotective benefit with the lowest attributable risk. The standard of care now mandates individualised risk stratification using the FRAX score (bone fracture risk), Framingham cardiovascular risk score, personal and family history of hormone-sensitive malignancies, and baseline hormone panels before any regimen is prescribed. Modern HRT is a precision-medicine discipline. Clinicians select from systemic estrogen-only therapy (for hysterectomised women), combined estrogen-progestogen therapy (for women with an intact uterus), tibolone (a synthetic steroid with estrogenic, progestogenic, and weak androgenic activity), and low-dose vaginal estrogen (for isolated genitourinary syndrome of menopause, or GSM). Bioidentical hormone therapy (BHT)—using 17β-estradiol and micronised progesterone structurally identical to endogenous hormones—is increasingly preferred over synthetic conjugated equine estrogens and medroxyprogesterone acetate because of its superior metabolic and breast-safety profile. Compounded bioidentical hormones remain controversial and are not recommended by major societies including NAMS, BMS, and IMS without robust quality-control assurance.
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Peri-menopausal or post-menopausal women (natural or surgical) with moderate-to-severe vasomotor symptoms (≥7 hot flushes/day or significant night sweats) significantly impairing quality of life • Women with confirmed premature ovarian insufficiency (POI) aged under 40, where HRT is strongly recommended until the age of natural menopause (51 years) • Women with DXA-confirmed osteopenia (T-score −1.0 to −2.5) or osteoporosis (T-score ≤ −2.5) for whom antiresorptive therapy alone is insufficient or not tolerated • Women experiencing symptomatic genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs) unresponsive to non-hormonal lubricants • Women with surgical menopause secondary to bilateral oophorectomy, regardless of age at surgery • Transgender men on testosterone therapy who require oestrogen supplementation for bone protection • REQUIRED DIAGNOSTICS BEFORE INITIATION: • Serum FSH, LH, 17β-estradiol, total and free testosterone, SHBG, AMH (if peri-menopausal) • Full lipid panel, fasting glucose/HbA1c, liver function tests, renal function • Thyroid function panel (TSH, Free T4) to exclude hypothyroidism as a mimicker • Mammography (within 12 months) and clinical breast examination • Pap smear / cervical cytology (within recommended screening interval) • Pelvic ultrasound (endometrial thickness baseline; transvaginal preferred) • DXA bone mineral density scan (lumbar spine L1–L4 and femoral neck) • Blood pressure measurement and BMI; thrombophilia screen (Factor V Leiden, prothrombin gene mutation, antiphospholipid antibodies) if personal or family history of VTE • ABSOLUTE CONTRAINDICATIONS: • Personal history of estrogen-receptor-positive (ER+) breast cancer or endometrial cancer (Stage II+) • Active or recent (within 12 months) venous thromboembolism (DVT or pulmonary embolism) not on anticoagulation • Untreated endometrial hyperplasia with atypia • Active liver disease with elevated transaminases >3× ULN • Unexplained vaginal bleeding under investigation • Recent acute arterial thromboembolic event (myocardial infarction, stroke) within 6 months • Known hereditary thrombophilia (e.g., Protein C/S deficiency, antithrombin III deficiency) — systemic oral HRT; transdermal route may be considered individually • RELATIVE CONTRAINDICATIONS (individualised risk-benefit discussion required): • Well-controlled hypertension (transdermal preferred over oral) • Gallbladder disease (transdermal preferred) • Migraine with aura (transdermal, low-dose preferred) • Strong family history of ER+ breast cancer (BRCA1/2 carrier status should be confirmed)
Treatment Options & Approaches
HRT is not a single drug but a spectrum of individualised regimens selected according to menopausal status, uterine status, symptom profile, route preference, and risk stratification. 1. SYSTEMIC ORAL HRT • Estrogen-only therapy: Conjugated equine estrogens (CEE) 0.3–0.625 mg/day or 17β-estradiol 1–2 mg/day (for hysterectomised women). • Combined continuous combined (CCC): Daily 17β-estradiol + micronised progesterone 100–200 mg — preferred for post-menopausal women (>12 months amenorrhoea) seeking amenorrhoea. • Sequential (cyclical) therapy: Estradiol daily + progestogen for 10–14 days per cycle — preferred for peri-menopausal women to maintain predictable withdrawal bleeds. • Tibolone 2.5 mg/day: Synthetic steroid with mixed estrogenic, progestogenic, and androgenic activity; suited for post-menopausal women with concomitant libido concerns. Not recommended within 5 years of breast cancer diagnosis. • Key limitation of oral route: First-pass hepatic metabolism elevates SHBG, triglycerides, and clotting factors (renin substrate), modestly increasing VTE risk compared to non-oral routes. 2. TRANSDERMAL DELIVERY SYSTEMS (PREFERRED ROUTE FOR MOST PATIENTS) • Matrix patches (e.g., Estradot, Climara): Deliver 25–100 µg/day 17β-estradiol through skin twice weekly or weekly; bypasses hepatic first-pass — neutral effect on coagulation and triglycerides, lower VTE risk vs. oral. • Estradiol gel (Oestrogel, Sandrena): 0.5–1.5 mg/day applied to inner arm or thigh; highly titratable. • Estradiol spray (Lenzetto): Metered-dose transdermal spray; 1–3 actuations/day. • Transdermal progestogen: Progesterone gel (Crinone) or Norethisterone-acetate patches (Estalis) used in combination. 3. SUBCUTANEOUS PELLET IMPLANTS (BIOIDENTICAL HORMONE PELLET THERAPY) • Compounded crystalline 17β-estradiol pellets (25–75 mg) and/or testosterone pellets (12.5–75 mg) inserted subcutaneously into the upper outer buttock or lower abdominal wall via a 4–5 mm incision under local anaesthesia (lidocaine 1%). • Procedure time: 10–15 minutes; no sutures required (Steri-Strips only). • Duration of action: 3–6 months; delivers stable, non-pulsatile serum levels without daily administration burden. • Particularly suited for: Women with malabsorption syndromes, poor patch adherence, or seeking testosterone supplementation for libido, fatigue, and cognitive function. • Monitoring: Serum estradiol and testosterone levels checked at 4–6 weeks post-insertion to confirm therapeutic range (estradiol 40–120 pg/mL; testosterone 70–150 ng/dL for women). 4. INTRAUTERINE PROGESTERONE DELIVERY • Levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena 52 mg): Delivers 20 µg/day LNG locally to the endometrium, providing progestogen endometrial protection while systemic estrogen is administered via any route. Reduces systemic progestogen side-effects (bloating, mood changes). Approved for HRT combination use in multiple international guidelines (BMS, ESHRE). 5. VAGINAL / LOCAL ESTROGEN (GENITOURINARY SYNDROME OF MENOPAUSE) • Ultra-low-dose vaginal estradiol tablets (Vagifem 10 µg), vaginal ring (Estring 7.5 µg/day), or estradiol cream: Minimal systemic absorption; does not require concomitant progestogen in most cases; safe even in most women with a history of breast cancer (per NAMS 2022 position statement). • Ospemifene 60 mg/day (oral SERM): For women unwilling to use vaginal preparations; effective for dyspareunia. • Prasterone (intravaginal DHEA 6.5 mg/day): Locally converted to estradiol and testosterone; FDA-approved for dyspareunia. 6. TESTOSTERONE SUPPLEMENTATION FOR WOMEN • Indicated for hypoactive sexual desire disorder (HSDD) unresponsive to estrogen optimisation. • Delivered via compounded transdermal cream (1% testosterone) or off-label use of male transdermal gels at female doses (1/10th of male dose). • Monitoring: Total testosterone, free testosterone, SHBG, haematocrit every 3–6 months. 7. NON-HORMONAL ADJUNCTS (for women with contraindications to HRT) • SSRIs/SNRIs: Paroxetine 7.5 mg (FDA-approved), Venlafaxine 75 mg for vasomotor symptoms. • Fezolinetant (Veoza): First-in-class neurokinin 3 receptor antagonist (NK3R); FDA-approved May 2023; reduces hot flush frequency by ~60% without systemic hormonal activity — critical option for ER+ breast cancer survivors. • Gabapentin 300 mg nocte: Off-label; useful for night sweats and sleep disruption. • Clonidine 50–150 µg/day: Modest efficacy for vasomotor symptoms in women with cardiovascular comorbidity.
Восстановление
PHASE 1 — PRE-TREATMENT EVALUATION (Days 1–7, typically remote + on-site Day 1) • Day 1 (Tele-consultation with GAF Healthcare): Upload existing medical records, current medications list, previous hormone test results. GAF's partner gynaecologist or reproductive endocrinologist reviews history and pre-authorises a standardised pre-HRT investigation panel. • Day 1–3 (On-site Investigations): Arrive at the hospital; complete fasting bloodwork (hormone panel, lipids, glucose, LFTs, TFTs, thrombophilia screen if indicated), mammography, pelvic transvaginal ultrasound, DXA scan, BP and BMI assessment. Pap smear performed if overdue. • Day 4–5 (Results Review and Regimen Design): Gynaecologist reviews all results and applies validated risk-stratification tools. Breast cancer risk: Tyrer-Cuzick 10-year model. VTE risk: personal/family history + thrombophilia screen. Bone fracture risk: FRAX score. Cardiovascular risk: Framingham 10-year score. A written, individualised HRT prescription with route, formulation, dose, and monitoring schedule is issued. PHASE 2 — HRT INITIATION (Day 5–7) • ORAL / TRANSDERMAL / VAGINAL REGIMEN: No hospital admission required. Patient is educated (ideally with a written patient information leaflet) on correct application of patches, gel, or spray; importance of progestogen compliance; symptoms of VTE (leg swelling, chest pain, SOB) requiring emergency presentation; and expected timeline of symptom relief (vasomotor symptoms: 2–4 weeks; urogenital symptoms: 6–12 weeks; bone density improvement: 12–24 months). • SUBCUTANEOUS PELLET INSERTION (if selected): Performed as an outpatient procedure on Day 5–6. Skin is cleansed, local anaesthetic infiltrated, a trocar is inserted through a 4–5 mm incision in the upper outer buttock, pellet(s) deposited, and wound closed with Steri-Strips. Patient ambulates immediately. No sutures. Mild local bruising/tenderness for 3–5 days. Strenuous lower-body exercise avoided for 72 hours. PHASE 3 — SHORT-TERM RECOVERY AND TRAVEL CLEARANCE (Days 7–14) • For transdermal/oral/vaginal HRT: Fit-to-fly within 24–72 hours of prescription. No procedural recovery required. Patient carries a 3-month supply of medication and written prescription (translated if required) for customs clearance. • For pellet insertion: Rest for 48 hours; avoid swimming and submersion bathing for 5 days. Fit-to-fly typically at Day 5–7 post-procedure. Patient receives a detailed procedural record and insertion site photographs for the next treating physician. • Follow-up tele-consultation with GAF Healthcare's partner physician at 4–6 weeks post-initiation to review first symptom response, check for side-effects (breakthrough bleeding, breast tenderness, mood changes), and adjust dose if required. PHASE 4 — LONG-TERM MANAGEMENT (Months 1–12+) • Serum estradiol (and testosterone if supplemented) re-checked at 4–6 weeks. • Endometrial thickness ultrasound at 6 months for women on combined HRT with unexpected bleeding. • Annual mammography, blood pressure review, lipid panel, fasting glucose. • DXA scan at 2 years to assess bone density response. • Annual HRT review: assess continued benefit vs. risk; consider duration of use (guidelines support ongoing use as long as quality-of-life benefit outweighs risk, reviewed annually). • Milestone symptom relief timeline: Vasomotor symptoms (hot flushes/night sweats): 50–75% reduction at 4 weeks, maximal at 12 weeks. Sleep and mood: 4–8 weeks. Urogenital symptoms: 6–12 weeks. Bone density stabilisation: 12 months; improvement at 24 months.
Возможные риски
HRT is a safe and evidence-based intervention when prescribed to appropriately selected candidates, but patients must be counselled on the following specific, quantified risks: VENOUS THROMBOEMBOLISM (VTE): Oral combined HRT approximately doubles the background VTE risk (from ~1 to ~2 per 1,000 women per year). Transdermal estradiol at standard doses does NOT significantly increase VTE risk — this is a critical distinction supported by the ESTHER and WHI observational sub-analyses. Women with thrombophilia should receive transdermal estrogen only. BREAST CANCER: Combined estrogen-progestogen HRT is associated with a small absolute increased risk: approximately 4–8 extra cases per 10,000 women per year of use. This risk approximates that of drinking 1–2 alcoholic units/day or being overweight. Estrogen-only HRT (in hysterectomised women) is associated with no significant increased breast cancer risk at 5–7 years and possibly a reduced risk (WHI re-analysis, 2020). The risk decreases toward baseline within 5 years of stopping HRT. Risk is lower with bioidentical micronised progesterone than with synthetic progestogens (e-3N cohort study, France). CARDIOVASCULAR: HRT initiated within 10 years of menopause in healthy women under 60 does not increase and may reduce coronary heart disease risk (ELITE trial). Initiated after age 60 or >10 years post-menopause in women with established cardiovascular disease, HRT may carry increased risk and is not recommended for primary cardiovascular prevention. STROKE: Oral estrogen modestly increases ischemic stroke risk (~1.5× baseline). Transdermal estradiol at standard doses does not significantly increase stroke risk. ENDOMETRIAL SAFETY: Unopposed systemic estrogen in women with a uterus causes endometrial hyperplasia and significantly increases endometrial cancer risk. Adequate progestogen co-administration (or LNG-IUS use) completely mitigates this risk — compliance with the progestogen component is mandatory. OTHER CONSIDERATIONS: Breast tenderness (30% of women, usually transient), bloating and nausea (more common with oral routes, often resolving at 4–6 weeks), irregular bleeding in the first 3–6 months of sequential therapy (expected), and local skin reactions at patch sites (5–10%). Pellet insertion carries a <1% risk of infection, extrusion, or haematoma at the insertion site.
Почему GAF Healthcare
GAF Healthcare provides end-to-end non-medical coordination for all international patients pursuing HRT consultations and initiation in India or the UAE. INDIA — VISA AND ENTRY: • GAF Healthcare facilitates the Indian e-Medical Visa application (available to nationals of 156 countries), which is processed online within 72 hours and permits a 60-day stay extendable to 6 months. The invitation/support letter from the treating hospital, required for the e-Medical Visa, is prepared by GAF's visa coordination team within 24 hours of booking confirmation. • A companion e-Medical Attendant Visa is simultaneously arranged for one accompanying family member. UAE — VISA AND ENTRY: • Citizens of 47+ countries receive visa-on-arrival or visa-free access to the UAE for stays of 30–90 days. Nationals of countries requiring advance visa are assisted by GAF Healthcare through the UAE patient visa facilitation process via the treating hospital's international patient department (DHA-licensed centres in Dubai; DoH-licensed in Abu Dhabi). AIRPORT TRANSFERS AND IN-COUNTRY TRANSPORT: • Private air-conditioned vehicle transfers are arranged for all arrival and departure journeys, as well as inter-hospital or hotel-to-clinic transfers throughout the stay. • For patients with mobility limitations, wheelchair-accessible vehicles and hospital porter assistance are pre-arranged. ACCOMMODATION: • GAF Healthcare's partner hotels range from mid-range 3-star medical tourism properties (within 2 km of the treating hospital) to 5-star luxury wellness hotels, depending on patient preference and budget. • Accommodation for one attending companion is included in GAF's standard coordination package. • For extended stays (pellet follow-up, complex hormone titration), serviced apartment options with kitchenette facilities are arranged for patient dietary convenience. MEDICAL INTERPRETATION AND COMMUNICATION: • Dedicated patient coordinators fluent in English, Arabic, Russian, French, and Swahili are assigned to each case. • Medical interpreters are available for consultations in 20+ languages upon 48-hour advance notice. • All discharge documents, prescriptions, and investigation reports are provided in English and, upon request, translated into the patient's home language for continuity of care with their local physician. MEDICATION EXPORT AND CUSTOMS SUPPORT: • GAF Healthcare's pharmacy coordination team ensures that all prescribed HRT medications are dispensed in their original branded, sealed packaging with manufacturer lot numbers and expiry dates, accompanied by a letter from the treating physician (in English and the patient's home language) for customs clearance at the patient's home country border. • Controlled substances (e.g., testosterone preparations) are dispensed with a narcotic/controlled-substance export certificate where applicable.
Частые вопросы о процедуре «Hormone Replacement Therapy (HRT)»
What is the cost of Hormone Replacement Therapy (HRT) in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after starting HRT?
What is the success rate of Hormone Replacement Therapy, and how is it measured?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «hormone replacement therapy (hrt)» в Бангалор, Индия
Найдите лучшие больницы для «hormone replacement therapy (hrt)» в Бангалор, Индия
На этой странице представлено 10 больниц в Бангалор, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Hormone Replacement Therapy (HRT)» в Бангалор, Индия
Сколько больниц направления «Гинекология» представлено в Бангалор, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Бангалор, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Hormone Replacement Therapy (HRT)» в Бангалор, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.